Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
The DOI matches its Crossref record.
Abstract
Advances in genetic and protein engineering and the ability to maintain proliferating mammalian cells in vitro, has allowed reverse engineering of antibodies, i.e. generation of antibodies having specificity for self-antigens. Thus, the lethal consequence of horror autotoxicus, anti-self-responses as envisaged by Paul Ehrlich (1854-1915), has been turned to advantage for treatment of multiple disease states. In order to reap these benefits, it is essential that, in addition to target specificity, the antibody is customised to deliver appropriate downstream biologic effector activities. Genetic engineering allows the development of any chosen isotype; however, The IgG class predominates in human serum and the majority of monoclonal antibody (mAb) therapeutics are based on the IgG format. This review focuses on the structure and function of the four human IgG isotypes (subclasses) and the biologic functions that their immune complexes activate through interactions with cellular Fc receptors (FcγR & FcRn) and/or the C1q component of complement. The long catabolic half-life (~21 days) of IgG contributes to its efficacy as a therapeutic. Each human IgG subclass exhibits a unique profile of biologic activities that are dependent on the glycoform profile of the IgG-Fc. Our current understanding of IgG structure/function relationships allows protein and glycosylation engineering of the IgG-Fc to enhance or eliminate biologic activities and the generation of therapeutics optimal for a given disease indication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
“…can improve recombinant protein properties such as increase their stability and half-life in blood circulation and decrease their immunogenicity (Ashwell and Harford, 1982; Runkel et al., 1998; Ghaderi et al., 2010; Ghaderi et al., 2012; Jefferis, 2016a; Jefferis, 2016b; Kuriakose et al., 2016).”
BackgroundCapillary Electrophoresis Separations of Glycans
Lu, G., Crihfield, C. L., Gattu, S., Veltri, L. M., & Holland, L. A. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00669 · Cited by 174
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
“is unexpected because IgG serum t1/2 is dominantly regulated by the FcRn (13).”
BackgroundInfluentialGlycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Metadata
- Authors
- Jefferis, R.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-12-13
- Volume
- 17
- Issue
- 15
- Pages
- 1333-1347
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2548126769
- Cited by
- 35
- References
- 0
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities. https://app.cochat.ai/papers/10.2174/1389201017666161029225929
- The paper
- Jefferis, R. (2016). Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities. Current Pharmaceutical Biotechnology. https://doi.org/10.2174/1389201017666161029225929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.